Paxlovid does not significantly cut COVID hospitalization in older vaccinated adults, study ...
The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to ...
新型コロナ感染阻止へ……新たな「切り札」登場か 経鼻ワクチンが ...
新型コロナウイルス感染症（COVID-19）の次世代経鼻ワクチンは、従来の注射型のワクチンにはできなかった、人から人へのウイルスの伝播を阻止できる可能性のあることが、動物実験で示された。この経鼻ワクチンが投与されたハムスターは、ウイルスに感染しても他 ...
Medscape14 時間
Doubled Paxlovid Prescriptions Show No Benefit in Vaccinated Older Adults, Study Finds
Adults aged more than 70 who received more prescriptions for nirmatrelvir-ritonavir did not show decreased rates of ...
M31 日
XBB.1.5系統対応コロナワクチンの予防効果と経時的変化
米国退役軍人保健局で、新型コロナウイルス感染症（COVID-19）のオミクロン株XBB.1.5系統対応1価ワクチンの有効性およびその経時的変化をtarget trial emulationで検討。マッチさせたワクチン接種者と非接種者の58万7137組（男性91.3％、平均年齢69.9歳）を対象とし、ワクチン有効性（VE）を推算した。 その結果、平均追跡期間176日での新型コロナウイルス（SARS- ...
Time5 日
Paxlovid May Not Significantly Benefit Vaccinated Seniors, Study Says
Most of us are pretty adept by now at managing COVID-19, with an armor of past infections, vaccinations, self-tests, and antiviral medications like Paxlovid. In the latest study, however ...
News Medical on MSN4 日
Paxlovid's promise fades: Vaccinated seniors see minimal COVID-19 protection
Paxlovid does not significantly reduce COVID-19 hospitalization and mortality among vaccinated older adults, according to new UCLA-led research.
News Medical on MSN7 日
Lasting impact of long COVID and the protective benefits of vaccination
Long COVID duration did not affect health outcomes; however, COVID-19 vaccination status was associated with better PROMIS ...